137 related articles for article (PubMed ID: 19118524)
21. Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor.
Campana G; Pasini P; Roda A; Spampinato S
Biochem Pharmacol; 2005 Jun; 69(12):1755-63. PubMed ID: 15935148
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-1beta stimulates acute phase response and C-reactive protein synthesis by inducing an NFkappaB- and C/EBPbeta-dependent autocrine interleukin-6 loop.
Kramer F; Torzewski J; Kamenz J; Veit K; Hombach V; Dedio J; Ivashchenko Y
Mol Immunol; 2008 May; 45(9):2678-89. PubMed ID: 18262272
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia downregulates farnesoid X receptor via a hypoxia-inducible factor-independent but p38 mitogen-activated protein kinase-dependent pathway.
Fujino T; Murakami K; Ozawa I; Minegishi Y; Kashimura R; Akita T; Saitou S; Atsumi T; Sato T; Ando K; Hara S; Kikugawa K; Hayakawa M
FEBS J; 2009 Mar; 276(5):1319-32. PubMed ID: 19187229
[TBL] [Abstract][Full Text] [Related]
24. Expression and activation of the farnesoid X receptor in the vasculature.
Bishop-Bailey D; Walsh DT; Warner TD
Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3668-73. PubMed ID: 14990788
[TBL] [Abstract][Full Text] [Related]
25. Pigment epithelium-derived factor (PEDF) blocks the interleukin-6 signaling to C-reactive protein expression in Hep3B cells by suppressing Rac-1 activation.
Yoshida T; Yamagishi S; Nakamura K; Matsui T; Imaizumi T; Inoue H; Ueno T; Sata M
Life Sci; 2006 Oct; 79(21):1981-7. PubMed ID: 16876827
[TBL] [Abstract][Full Text] [Related]
26. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.
Nicolaou KC; Evans RM; Roecker AJ; Hughes R; Downes M; Pfefferkorn JA
Org Biomol Chem; 2003 Mar; 1(6):908-20. PubMed ID: 12929628
[TBL] [Abstract][Full Text] [Related]
27. Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor.
Savkur RS; Bramlett KS; Michael LF; Burris TP
Biochem Biophys Res Commun; 2005 Apr; 329(1):391-6. PubMed ID: 15721319
[TBL] [Abstract][Full Text] [Related]
28. 5Alpha-bile alcohols function as farnesoid X receptor antagonists.
Nishimaki-Mogami T; Kawahara Y; Tamehiro N; Yoshida T; Inoue K; Ohno Y; Nagao T; Une M
Biochem Biophys Res Commun; 2006 Jan; 339(1):386-91. PubMed ID: 16300737
[TBL] [Abstract][Full Text] [Related]
29. Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray.
Higashiyama H; Kinoshita M; Asano S
Acta Histochem; 2008; 110(1):86-93. PubMed ID: 17963822
[TBL] [Abstract][Full Text] [Related]
30. FXR: a metabolic regulator and cell protector.
Wang YD; Chen WD; Moore DD; Huang W
Cell Res; 2008 Nov; 18(11):1087-95. PubMed ID: 18825165
[TBL] [Abstract][Full Text] [Related]
31. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice.
Szalai AJ; van Ginkel FW; Dalrymple SA; Murray R; McGhee JR; Volanakis JE
J Immunol; 1998 Jun; 160(11):5294-9. PubMed ID: 9605127
[TBL] [Abstract][Full Text] [Related]
32. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR).
Flatt B; Martin R; Wang TL; Mahaney P; Murphy B; Gu XH; Foster P; Li J; Pircher P; Petrowski M; Schulman I; Westin S; Wrobel J; Yan G; Bischoff E; Daige C; Mohan R
J Med Chem; 2009 Feb; 52(4):904-7. PubMed ID: 19159286
[TBL] [Abstract][Full Text] [Related]
33. The expanding role of the bile acid receptor FXR in the small intestine.
Cariou B; Staels B
J Hepatol; 2006 Jun; 44(6):1213-5. PubMed ID: 16618512
[No Abstract] [Full Text] [Related]
34. Effects of coumestrol on lipid and glucose metabolism as a farnesoid X receptor ligand.
Takahashi M; Kanayama T; Yashiro T; Kondo H; Murase T; Hase T; Tokimitsu I; Nishikawa J; Sato R
Biochem Biophys Res Commun; 2008 Aug; 372(3):395-9. PubMed ID: 18457666
[TBL] [Abstract][Full Text] [Related]
35. A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids.
Shih DM; Kast-Woelbern HR; Wong J; Xia YR; Edwards PA; Lusis AJ
J Lipid Res; 2006 Feb; 47(2):384-92. PubMed ID: 16269825
[TBL] [Abstract][Full Text] [Related]
36. New targets in and potential treatments for cholesterol gallstone disease.
Doggrell SA
Curr Opin Investig Drugs; 2006 Apr; 7(4):344-8. PubMed ID: 16625821
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of genotype 1 hepatitis C virus replication by bile acids through FXR.
Scholtes C; Diaz O; Icard V; Kaul A; Bartenschlager R; Lotteau V; André P
J Hepatol; 2008 Feb; 48(2):192-9. PubMed ID: 18096266
[TBL] [Abstract][Full Text] [Related]
38. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development.
Maran RR; Thomas A; Roth M; Sheng Z; Esterly N; Pinson D; Gao X; Zhang Y; Ganapathy V; Gonzalez FJ; Guo GL
J Pharmacol Exp Ther; 2009 Feb; 328(2):469-77. PubMed ID: 18981289
[TBL] [Abstract][Full Text] [Related]
39. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation.
Hu T; Chouinard M; Cox AL; Sipes P; Marcelo M; Ficorilli J; Li S; Gao H; Ryan TP; Michael MD; Michael LF
J Biol Chem; 2006 Dec; 281(52):39831-8. PubMed ID: 17065154
[TBL] [Abstract][Full Text] [Related]
40. Farnesoid X receptor agonists in biliary tract disease.
Fiorucci S; Baldelli F
Curr Opin Gastroenterol; 2009 May; 25(3):252-9. PubMed ID: 19300246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
